Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

Rhea-AI Summary

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will host a conference call on March 1, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results and recent business developments. Investors can access the call via phone or through the company’s website. Biohaven specializes in innovative therapies for neurological and neuropsychiatric conditions, with an FDA-approved product, NURTEC^® (rimegepant), and a promising pipeline targeting migraine, OCD, and more.

Positive

• Biohaven is preparing to report its full year 2020 financial results, potentially showcasing revenue growth.
• The company has successfully launched NURTEC^® for acute migraine treatment, contributing to its commercial portfolio.

Negative

• None.

NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will host a conference call and webcast to report fourth quarter and full year 2020 financial results and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday March 1, 2021 at 8:30 a.m. ET.

To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the "Investors" section of Biohaven's website at www.biohavenpharma.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13715754. An archived webcast will be available on Biohaven's website.  

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC^® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder,  and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-to-report-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-developments-on-march-1-2021-301234050.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

FAQ

When will Biohaven report its financial results for 2020?

Biohaven will report its financial results on March 1, 2021, at 8:30 a.m. ET.

What is the main focus of Biohaven Pharmaceutical?

Biohaven focuses on therapies for neurological and neuropsychiatric diseases, including migraine and rare disorders.

How can I access the Biohaven conference call?

You can access the conference call by dialing 877-407-9120 (domestic) or 412-902-1009 (international) or through their website.

What products does Biohaven offer?

Biohaven offers NURTEC^® (rimegepant) for acute migraine and has a pipeline targeting various neurological conditions.